{
    "2018-06-29": [
        [
            {
                "time": "",
                "original_text": "泰格医药：2018年半年度业绩报告预告",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "2018年",
                        "半年度",
                        "业绩报告",
                        "预告"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药：上半年净利预增65%-95%",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "上半年",
                        "净利",
                        "预增",
                        "65%-95%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级] 医药生物行业2018年中期投资策略：给确定性溢价 增长为王",
                "features": {
                    "keywords": [
                        "推荐评级",
                        "医药生物",
                        "2018年",
                        "中期",
                        "投资策略",
                        "确定性溢价",
                        "增长为王"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}